# 2026-03326: FDA Reviews Rules for Safe Drug Production Practices

2026-03326, Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice (CGMP): Manufacturing, Processing, Packing, and Holding of Drugs; GMP for Finished Pharmaceuticals (Including Active Pharmaceutical Ingredients) and the Advanced Manufacturing Technologies Designation Program, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-02-20, effective 2026-04-21 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-03326
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-03326
- Title: Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice (CGMP): Manufacturing, Processing, Packing, and Holding of Drugs; GMP for Finished Pharmaceuticals (Including Active Pharmaceutical Ingredients) and the Advanced Manufacturing Technologies Designation Program
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 8249
- Published: 2026-02-20
- Effective: 2026-04-21
- Comments close: 2026-04-21
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Reviews Rules for Safe Drug Production Practices

## Summary

The FDA wants your thoughts on how they collect info about making and handling medicines safely, including new tech in drug manufacturing. This affects drug makers and anyone involved in producing medicines, with a comment deadline of April 21, 2026. No big costs or changes yet—just a chance to help shape future rules!

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection associated with CGMP for drugs, finished pharmaceuticals, including active pharmaceutical ingredients (APIs), and the advanced manufacturing technologies (AMT) designation program.

## Effects PRIA read

- 60-Day Public Comment Window: benefit, low. The FDA is asking for public comment on its proposed information collection related to Current Good Manufacturing Practice (CGMP) and the Advanced Manufacturing Technologies (AMT) designation program. Comments must be submitted by April 21, 2026, through https://www.regulations.gov or by mail to th…
- Estimated Annual Recordkeeping Burden: cost, high. FDA estimates annual recordkeeping for CGMP as 1,260 API manufacturers (322,560 records at 0.82 hours each = 264,499 hours) and 3,270 finished pharmaceuticals manufacturers (977,730 records at 0.64 hours each = 625,747 hours). The total annual records are 1,300,319 with a total annual burden of 890…
- Medical Gas Burden Removed Here: benefit, high. FDA removed activities and burden attributable to medical gas requirements from this collection, resulting in a decrease of 396,293 hours and 639,491 responses annually; medical gas CGMP requirements are now under OMB control number 0910-0906.
- AMT Designation Program Burden: cost, low. The Advanced Manufacturing Technologies (AMT) designation program is included in the information collection; FDA estimates 20 recordkeepers with 20 total records for AMT activities and an average burden of 10 hours per record, totaling 200 hours annually.
- No Capital or O&M Costs: benefit, low. FDA states there are no capital or operating and maintenance (O&M) costs associated with this information collection.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-03326 on federalregister.gov](https://www.federalregister.gov/documents/2026/02/20/2026-03326/agency-information-collection-activities-proposed-collection-comment-request-current-good)
- [2026-03326 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-02-20/pdf/2026-03326.pdf)

## Related
- [Previous: 2026-03325, Overhead Door Counterbalance Torsion Springs From India; Determinations](https://policyrisk.com/federal-register/2026-03325)
- [Next: 2026-03327, Public Meetings of the Advisory Committee on Landslides](https://policyrisk.com/federal-register/2026-03327)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-03326 (as of 2026-06-08).
